Description

Ticagrelor is a potent, direct-acting, and reversibly binding P2Y12 receptor antagonist, classified as a cyclopentyltriazolopyrimidine (CPTP) agent. It is a critical active pharmaceutical ingredient (API) used in the formulation of antiplatelet medications to prevent atherothrombotic events. This compound is essential for pharmaceutical manufacturers and research institutions developing treatments for acute coronary syndrome (ACS) and other cardiovascular conditions where platelet aggregation inhibition is required. Ticagrelor CAS NO 1265919-24-1 represents a high-value therapeutic agent with significant clinical importance.

Application

• Pharmaceutical API: Primary use as the active ingredient in oral antiplatelet tablets for the prevention of thrombotic cardiovascular events.
• Cardiovascular Medicine: Formulation into medications for patients with Acute Coronary Syndrome (ACS), including unstable angina, non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI).
• Secondary Prevention: Used in the long-term management of patients with a history of myocardial infarction to reduce the rate of recurrent cardiovascular death and myocardial infarction.
• Clinical Research: Serves as a reference standard and key material in pharmacokinetic, pharmacodynamic, and bioequivalence studies.
• Generic Drug Development: A critical target molecule for manufacturers developing bioequivalent generic versions of established antiplatelet therapies.
• Combination Therapy Research: Investigated in combination with other anticoagulants or antiplatelet agents for optimized therapeutic protocols.

Basic Information

Product Name	Ticagrelor
CAS No.	1265919-24-1
Molecular Formula	C23H28F2N6O4S
Molecular Weight	522.57 g/mol
Synonyms	(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol; AZD6140; AR-C126532XX; Brillinta (Trade Name); Brilique (Trade Name); Possia (Trade Name); Ticagrelorum; Ticagrelor API
EINECS	Contact for details

Quality Control

Our Ticagrelor is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing to ensure it meets stringent specifications for identity, purity, and potency, aligning with ICH Q7 guidelines for active pharmaceutical ingredients. Certificates of Analysis (COA) detailing results for assay, related substances, residual solvents, and microbiological quality are provided with every shipment. We support compliance with major pharmacopoeial standards, including USP and EP monographs where applicable.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). Due to its hygroscopic (moisture-sensitive) nature, the container must be kept tightly sealed in a dry environment to prevent degradation. For long-term storage, consider the use of desiccants.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time corresponds to reference standard
Assay (HPLC)	98.0% - 102.0% (on anhydrous basis)
Related Substances (HPLC)	Individual impurity: NMT 0.15% Total impurities: NMT 0.5%
Water Content (KF)	NMT 1.0%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Heavy Metals	NMT 20 ppm
Sulfated Ash	NMT 0.1%
Microbiological Enumeration	Complies with USP <61> / Ph. Eur. 2.6.12

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.